Furthermore, PAI-1 inhibitors have been proposed as novel antithrombotic agents that could help reduce vascular complications in diabetic patients, offering new therapeutic avenues for managing diabetes-associated cardiovascular risks (Altalhi et al., 2021). The gene discussed is SERPINE1; the disease is diabetes mellitus.